Imamura Keiko
,
Izumi Yuishin
,
Banno Haruhiko
,
Uozumi Ryuji
,
Morita Satoshi
,
Egawa Naohiro
,
Ayaki Takashi
,
Nagai Makiko
,
Nishiyama Kazutoshi
,
Watanabe Yasuhiro
,
Hanajima Ritsuko
,
Oki Ryosuke
,
Fujita Koji
,
Takahashi Naoto
,
Ikeda Takafumi
,
Shimizu Akira
,
Morinaga Akiko
,
Hirohashi Tomoko
,
Fujii Yosuke
,
Takahashi Ryosuke
,
Inoue Haruhisa
… Dose escalation and maximum tolerated dose are determined by the safety assessment committee comprising oncologists/haematologists and neurologists based on the incidence of dose-limiting toxicity in the first 4 weeks of the treatment at each dose level. … A recommended phase II dose is determined by the safety assessment committee on completion of the 12-week study treatment in all subjects at all dose levels. …
IR